Could entresto help adult hearts born with defects?

NCT ID NCT06693674

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug Entresto (sacubitril-valsartan) can improve heart structure and function in adults with congenital heart disease. 45 participants will take either Entresto or a placebo for 52 weeks. Researchers will measure heart changes, blood markers, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Entresto (sacubitril-valsartan)

What this could lead to

If it works, this could point toward a treatment to improve heart function and daily life for adults with congenital heart disease.

What could go wrong

This is a small, early-phase trial with only 45 people, so results may not apply to everyone. The drug also has risks like low blood pressure and high potassium.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL HEART DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital heart disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••